Gut check: Does a hospital stay set patients up for sepsis by disrupting the microbiome?
6/02/2015
U-M study shows higher rate of sepsis within 90 days of hospitalization, especially after care that's likely to alter the balance of microbes in the gutCan a routine hospital stay upset the...
Immunotherapy heralds 'new era' for cancer treatment
6/02/2015
Two new studies show immunotherapy to be highly effective against melanoma and lung cancer, with experts claiming the treatment may replace chemotherapy in the next few years.
Chronic lymphocytic leukaemia: Interim analysis data of Phase 3 HELIOS trial announced
6/02/2015
Data from a pre-planned interim analysis of the phase 3 CLL3001 (HELIOS) trial show that, at a median follow-up of 17.
Investigators from Montefiore Einstein Center for Cancer Care have announced new findings from an extensive literature review published in the Annals of Oncology.
Drug combination controls breast cancer for over twice as long
6/02/2015
A new drug delays the progression of advanced breast cancer by over twice as long when used in combination with standard treatment, compared to standard treatment alone, a major clinical trial...
Breakthrough blood cancer drug finally gets green light for NHS use
6/02/2015
From today (June 2nd), clinicians in England and Wales will be able to prescribe Gazyvaro for eligible patients with chronic lymphocytic leukaemia (CLL) on the NHS.
Major funding award for risk prediction programme to provide one test for all women-specific cancers
6/02/2015
The European Commission has awarded an unprecedented €7.9m grant to a ground-breaking research project, led by University College London, which has the potential to predict and prevent the...
Researcher discovers metabolite of prostate cancer drug more effective at treating aggressive tumors
6/02/2015
Cleveland Clinic researchers have discovered for the first time that a metabolite of an FDA-approved drug for metastatic prostate cancer, abiraterone (Abi), has more anti-cancer properties than its...
Novartis has announced data from the Phase III COMBI-d study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the...
A large cooperative-group study directed by the Alliance for Clinical Trials in Oncology has confirmed previous evidence that the drug lenalidomide delays time to disease progression for patients...